Abstract

Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62% of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of > 40% from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95% CI: 17.4, 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0.0001). In total, 31 of the 339 patients (9.1%) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.

Author Details

Authors

• M.H. Habil
• H. Gondoyoewono
• H.R. Chaudhry
• U. Samanwongthai
• A.R.A. Hamid
• I.T. Hashmi
• R. Budiman
• A.G. Knowles
• R. Buenaventura

Departments

• ¹ Department of Psychological Medicine, University of Malaya, Kuala Lumpur, Malaysia,
• ² Department of Psychiatry, Trisakti University, Jakarta, Indonesia,
• ³ Department of Psychiatry, Fatima Jinnah Medical College & Sir Ganga Ram Hospital, Lahore, Pakistan,
• ⁴ Srithanya Psychiatric Hospital, Nonthaburi, Thailand,
• ⁵ Department of Psychiatry, Universiti Kebangsaan Malaysia, Bangi, Malaysia,
• ⁶ Department of Psychiatry, Shalimar Hospital, Lahore, Pakistan,
• ⁷ Department of Psychiatry, University of Indonesia, Depok and Jakarta, Indonesia,
• ⁸ Clinical Outcomes Research Institute, Eli Lilly Australia Pty Ltd., West Ryde, NSW, Australia, and
• ⁹ Eli Lilly (Philippines), Inc., Quezon City, Philippines

Address

M.H. Habil, MBBS, MpsychMed, Jabatan Perubatan Psikologi, Fakulti Perubatan, Universiti Malaya, 50603 Kuala Lumpur, Malaysia
Email: [email protected]

Citation